S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69

Stealth BioTherapeutics Stock Forecast, Price & News

-0.06 (-7.32%)
(As of 01/21/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
52,326 shs
Average Volume
73,366 shs
Market Capitalization
$43.76 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive MITO News and Ratings via Email

Sign-up to receive the latest news and ratings for Stealth BioTherapeutics and its competitors with MarketBeat's FREE daily newsletter.

Stealth BioTherapeutics logo

About Stealth BioTherapeutics

Stealth BioTherapeutics Corp. is a clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. The company was founded on April 3, 2006 and is headquartered in George Town, Cayman Islands.


Stealth BioTherapeutics Corp. ADS (MITO)
January 19, 2022 |  nasdaq.com
Stealth BioTherapeutics Receives Refusal to File Letter from the FDA
October 20, 2021 |  markets.businessinsider.com
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$21.09 million
Book Value
($0.20) per share


Net Income
$-57.46 million
Pretax Margin




Free Float
Market Cap
$43.76 million
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

1.53 out of 5 stars

Medical Sector

1082nd out of 1,419 stocks

Pharmaceutical Preparations Industry

523rd out of 685 stocks

Analyst Opinion: 3.5Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Stealth BioTherapeutics (NASDAQ:MITO) Frequently Asked Questions

Is Stealth BioTherapeutics a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Stealth BioTherapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Stealth BioTherapeutics stock.
View analyst ratings for Stealth BioTherapeutics
or view top-rated stocks.

How has Stealth BioTherapeutics' stock been impacted by Coronavirus?

Stealth BioTherapeutics' stock was trading at $1.5887 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, MITO stock has decreased by 52.2% and is now trading at $0.76.
View which stocks have been most impacted by COVID-19

Are investors shorting Stealth BioTherapeutics?

Stealth BioTherapeutics saw a increase in short interest in the month of December. As of December 31st, there was short interest totaling 60,000 shares, an increase of 57.9% from the December 15th total of 38,000 shares. Based on an average daily trading volume, of 153,000 shares, the days-to-cover ratio is currently 0.4 days.
View Stealth BioTherapeutics' Short Interest

When is Stealth BioTherapeutics' next earnings date?

Stealth BioTherapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, April 5th 2022.
View our earnings forecast for Stealth BioTherapeutics

How were Stealth BioTherapeutics' earnings last quarter?

Stealth BioTherapeutics Corp (NASDAQ:MITO) posted its quarterly earnings results on Thursday, November, 11th. The company reported ($0.02) earnings per share (EPS) for the quarter, meeting the Zacks' consensus estimate of ($0.02).
View Stealth BioTherapeutics' earnings history

What price target have analysts set for MITO?

2 Wall Street analysts have issued 1 year target prices for Stealth BioTherapeutics' stock. Their forecasts range from $3.00 to $4.00. On average, they expect Stealth BioTherapeutics' share price to reach $3.50 in the next year. This suggests a possible upside of 360.5% from the stock's current price.
View analysts' price targets for Stealth BioTherapeutics
or view top-rated stocks among Wall Street analysts.

Who are Stealth BioTherapeutics' key executives?

Stealth BioTherapeutics' management team includes the following people:
  • Irene P. McCarthy, Chief Executive Officer & Director
  • Robert J. Weiskopf, Chief Financial Officer
  • James R. Carr, Chief Clinical Development Officer
  • Martin P. Redmon, Chief Research & Development Officer
  • Brian D. Blakey, Chief Business Officer

What other stocks do shareholders of Stealth BioTherapeutics own?

When did Stealth BioTherapeutics IPO?

(MITO) raised $81 million in an initial public offering (IPO) on Friday, February 15th 2019. The company issued 6,200,000 shares at a price of $12.00-$14.00 per share. Jefferies, Evercore ISI and BMO Capital Markets acted as the underwriters for the IPO and Nomura was co-manager.

What is Stealth BioTherapeutics' stock symbol?

Stealth BioTherapeutics trades on the NASDAQ under the ticker symbol "MITO."

How do I buy shares of Stealth BioTherapeutics?

Shares of MITO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Stealth BioTherapeutics' stock price today?

One share of MITO stock can currently be purchased for approximately $0.76.

How much money does Stealth BioTherapeutics make?

Stealth BioTherapeutics has a market capitalization of $43.76 million and generates $21.09 million in revenue each year. The company earns $-57.46 million in net income (profit) each year or ($0.41) on an earnings per share basis.

How many employees does Stealth BioTherapeutics have?

Stealth BioTherapeutics employs 2,020 workers across the globe.

What is Stealth BioTherapeutics' official website?

The official website for Stealth BioTherapeutics is www.stealthbt.com.

Where are Stealth BioTherapeutics' headquarters?

Stealth BioTherapeutics is headquartered at 275 GROVE STREET SUITE 3-107, NEWTON MA, 02466.

How can I contact Stealth BioTherapeutics?

Stealth BioTherapeutics' mailing address is 275 GROVE STREET SUITE 3-107, NEWTON MA, 02466. The company can be reached via phone at 617-600-6888 or via email at [email protected].

This page was last updated on 1/23/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.